Vib Vzw

Vrije Universiteit Brussel

Katholieke Universiteit Leuven, Ku Leuven R&d

Life Sciences Research Partners Vzw

Sanofi

Universiteit Gent

Joost Schymkowitz

Jie Hui Xu

Peter Carmeliet

Bart De Strooper

Frederic Rousseau

Corentin Herbert

Wim Robberecht

Jie Xu

Frederik De Smet

Joost Van Durme

Ashok Ganesan

Frédéric Rousseau

Aleksandra Siekierska

Ivo Da Rocha Martins

The present invention relates to non-naturally occurring anti-bacterial peptides. More specifically the peptides can be used to treat multi-drug resistant bacterial infections. In addition, the present invention provides methods for producing anti-bacterial peptides.

Means and methods for treating bacterial infections

The present invention belongs to the field of functional proteomics and more particularly to the field of protein aggregation. The invention discloses a method for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and which induces aggregation upon contact with said target protein. The present invention also discloses such interferor molecules and their use in agrobiotech applications.

Means and methods for mediating protein interference

The disclosure provides a general method for the production of protein variants with a reduced aggregation propensity without affecting the thermodynamic stability of the variant with respect to the wild-type protein.

Means and methods for generating improved proteins

The present application relates to the field of single-domain antibodies (also called nanobodies), more particularly single-domain antibodies against SOD1 protein isoforms. It also relates to the use of these nanobodies in medicine. Accordingly, methods to treat a disease using these nanobodies are provided herein. The single-domain antibodies are particularly envisaged for treatment of ALS.

Single domain antibodies against SOD1 and their use in medicine

The disclosure relates to the fields of protein aggregation diseases including cancer. More specifically, it concerns a screening method for identifying compounds that inhibit or disrupt co-aggregation of one or more member proteins of a disease-related protein aggregome, in particular, a tumor-associated protein aggregome. Further, disclosed are agents and compounds identified by the screening method that can be applied to prevent or to treat protein aggregation diseases, such as cancer.

Methods for screening inhibitors of tumor associated protein aggregation

The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.

Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor

The invention belongs to the field of functional proteomics and, more particularly, to the field of protein aggregation. Described are methods for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and that induces aggregation upon contact with the target protein. The invention also discloses such interferer molecules and their use in therapeutic applications.

Growing community of inventors

Meensel-Kiezegem, Belgium

Joost Schymkowitz